Mechanisms of subtelomere recombination in telomerase deficient tumors

端粒酶缺陷肿瘤中亚端粒重组的机制

基本信息

  • 批准号:
    8587568
  • 负责人:
  • 金额:
    $ 23.41万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-15 至 2015-10-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Telomere maintenance in the absence of telomerase can occur by various mechanisms, collectively termed ALT, for alternative lengthening mechanisms. Nearly 10% of human tumors, often sarcomas or glioblastomas, lack the enzyme telomerase for telomere maintenance. In order to study these non- telomerase telomere maintenance mechanisms we are using E¿myc+mTR-/- mice, genetically deleted for the RNA component of telomerase (mTR), and crossed to E¿myc+ mice, which develop B-cell lymphoma. To test the role of recombination in these non-telomerase telomere maintenance mechanisms we are currently using an shRNA approach to inhibit various recombination genes, and then examining the change in growth rate of tumors. To understand more about the mechanisms we then assay the tumors for subtelomere recombination. In this proposal we intend to examine the contribution of genes involved in replication fork stalling, and the role of DNA repair by a novel mechanism known as break-induced replication. To monitor break-induced replication in mammalian cells, we will develop assays to detect the hallmarks of break-induced replication. These characteristics include loss of heterozygosity, non-reciprocal translocations, and segmental duplications. Finally during the independent phase we intend to examine the role of LINE-1 retrotransposition during break-induced replication and telomere maintenance. Non- LTR retrotransposons, referred to as LINE-1 or L1, account for a significant fraction of the mouse and human genomes. These mobile genetic elements move by an RNA intermediate using a mechanism called target-primed reverse transcription. In addition we found that retrotransposition can also occur at endogenous DNA breaks and dysfunctional telomeres. Furthermore, non-LTR retrotransposons in Drosophila entirely contribute to the mechanism of telomere maintenance. Thus we intend to examine whether non-LTR retrotransposons also contribute to telomere maintenance in both human and mouse cells and thus account for the occurrence of tumors lacking telomerase.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TAMMY A MORRISH其他文献

TAMMY A MORRISH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TAMMY A MORRISH', 18)}}的其他基金

Mechanisms of subtelomere recombination in telomerase deficient tumors
端粒酶缺陷肿瘤中亚端粒重组的机制
  • 批准号:
    8810655
  • 财政年份:
    2011
  • 资助金额:
    $ 23.41万
  • 项目类别:
Mechanisms of subtelomere recombination in telomerase deficient tumors
端粒酶缺陷肿瘤中亚端粒重组的机制
  • 批准号:
    8030254
  • 财政年份:
    2011
  • 资助金额:
    $ 23.41万
  • 项目类别:
Mechanisms of subtelomere recombination in telomerase deficient tumors
端粒酶缺陷肿瘤中亚端粒重组的机制
  • 批准号:
    8320132
  • 财政年份:
    2011
  • 资助金额:
    $ 23.41万
  • 项目类别:
Mechanisms of subtelomere recombination in telomerase deficient tumors
端粒酶缺陷肿瘤中亚端粒重组的机制
  • 批准号:
    8610259
  • 财政年份:
    2011
  • 资助金额:
    $ 23.41万
  • 项目类别:

相似海外基金

Roles of immune cells derived from clonal hematopoiesis in B-cell lymphomas
克隆造血来源的免疫细胞在 B 细胞淋巴瘤中的作用
  • 批准号:
    24K19213
  • 财政年份:
    2024
  • 资助金额:
    $ 23.41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identification of novel biomarkers for EBV-associated B-cell lymphomas arising in the oral cavity
口腔中出现的 EBV 相关 B 细胞淋巴瘤的新型生物标志物的鉴定
  • 批准号:
    23K15982
  • 财政年份:
    2023
  • 资助金额:
    $ 23.41万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
  • 批准号:
    10606730
  • 财政年份:
    2023
  • 资助金额:
    $ 23.41万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10566833
  • 财政年份:
    2023
  • 资助金额:
    $ 23.41万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10987699
  • 财政年份:
    2023
  • 资助金额:
    $ 23.41万
  • 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
  • 批准号:
    10541285
  • 财政年份:
    2022
  • 资助金额:
    $ 23.41万
  • 项目类别:
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
  • 批准号:
    10540952
  • 财政年份:
    2022
  • 资助金额:
    $ 23.41万
  • 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
  • 批准号:
    10703446
  • 财政年份:
    2022
  • 资助金额:
    $ 23.41万
  • 项目类别:
Therapeutic potential of novel antibody-oligonucleotide conjugate for intractable B-cell lymphomas
新型抗体-寡核苷酸缀合物治疗难治性 B 细胞淋巴瘤的潜力
  • 批准号:
    22K08497
  • 财政年份:
    2022
  • 资助金额:
    $ 23.41万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
  • 批准号:
    10707312
  • 财政年份:
    2022
  • 资助金额:
    $ 23.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了